Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Multiple Myeloma 81Neoplasms, Plasma Cell 27Neoplasms 13Brain Neoplasms 11Prostatic Neoplasms 10Central Nervous System Neoplasms 10Melanoma 9Leukemia 9Glioblastoma 8Gliosarcoma 7Glioma 7Leukemia, Lymphocytic, Chronic, B-Cell 6Carcinoma, Hepatocellular 6Recurrence 5Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Lymphoma, Mantle-Cell 5Lung Neoplasms 5Waldenstrom Macroglobulinemia 4Sarcoma 4Myelodysplastic-Myeloproliferative Diseases 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Immunoglobulin Light-chain Amyloidosis 4Carcinoma, Renal Cell 4Uveal Melanoma 3Oligodendroglioma 3Neuroblastoma 3Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3

Interventions

Epoetin Alfa 43Darbepoetin alfa 33epoetin beta 10ferric carboxymaltose 6Cyclosporine 4Cisplatin 4ferrous sulfate 3Radiotherapy 3Lenalidomide 3peginesatide 2luspatercept 2hematide 2fludarabine 2ferric gluconate 2continuous erythropoietin receptor activator 2Therapeutics 2Filgrastim 2Erythropoietin 2Dexamethasone 2Cyclophosphamide 2Brachytherapy 2Antilymphocyte Serum 2ACE-011 2thymoglobulin 1ruxolitinib 1roxadustat 1reolysin 1pegfilgrastim 1obinutuzumab 1leridistim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Anemia × Thalidomide × Clear all
NCT00053001 2013-06-26

Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 2 Completed
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡